Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Sang-Cheol | - |
dc.contributor.author | Gun, Suk Chyn | - |
dc.contributor.author | Mok, Chi Chiu | - |
dc.contributor.author | Khandker, Rezaul | - |
dc.contributor.author | Nab, Henk W. | - |
dc.contributor.author | Koenig, Andrew S. | - |
dc.contributor.author | Vlahos, Bonnie | - |
dc.contributor.author | Pedersen, Ron | - |
dc.contributor.author | Singh, Amitabh | - |
dc.date.accessioned | 2021-08-02T18:58:31Z | - |
dc.date.available | 2021-08-02T18:58:31Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2013-01 | - |
dc.identifier.issn | 1471-2474 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/26806 | - |
dc.description.abstract | Background Patient reported outcomes (PROs) are especially useful in assessing treatments for rheumatoid arthritis (RA) since they measure dimensions of health-related quality of life that cannot be captured using strictly objective physiological measures. The aim of this study was to compare the effects of combination etanercept and methotrexate (ETN + MTX) versus combination synthetic disease modifying antirheumatic drugs (DMARDs) and methotrexate (DMARD + MTX) on PRO measures among RA patients from the Asia-Pacific region, a population not widely studied to date. Patients with established moderate to severe rheumatoid arthritis who had an inadequate response to methotrexate were studied. Methods Patients were randomized to either ETN + MTX (N = 197) or DMARD + MTX (N = 103) in an open-label, active-comparator, multicenter study, with PRO measures designed as prospective secondary endpoints. The Health Assessment Questionnaire (HAQ), Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue), Medical Outcomes Short Form-36 Health Survey (SF-36), Hospital Anxiety and Depression Scale (HADS) and the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH) were used. Results Significantly greater improvements were noted for the ETN + MTX group at week16 for HAQ mean scores and for proportion of patients achieving HAQ score ≤ 0.5, compared to patients in the DMARD + MTX group. SF-36 Summary Scores for physical and mental components and for 6 of 8 health domains showed significantly greater improvements at week16 for the ETN + MTX group; only scores for physical functioning and role-emotional domains did not differ significantly between the two treatment arms. Greater improvements at week16 were noted for the ETN + MTX group for FACIT-Fatigue, HADS, and WPAI:GH mean scores. Conclusion Combination therapy using ETN + MTX demonstrated superior improvements using a comprehensive set of PRO measures, compared to combination therapy with usual standard of care DMARDs plus MTX in patients with established rheumatoid arthritis from the Asia-Pacific region. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.title | Improved health outcomes with Etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Bae, Sang-Cheol | - |
dc.identifier.doi | 10.1186/1471-2474-14-13 | - |
dc.identifier.scopusid | 2-s2.0-84871976126 | - |
dc.identifier.wosid | 000316558300001 | - |
dc.identifier.bibliographicCitation | BMC MUSCULOSKELETAL DISORDERS, v.14, pp.1 - 8 | - |
dc.relation.isPartOf | BMC MUSCULOSKELETAL DISORDERS | - |
dc.citation.title | BMC MUSCULOSKELETAL DISORDERS | - |
dc.citation.volume | 14 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 8 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Orthopedics | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Orthopedics | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | MODIFYING ANTIRHEUMATIC DRUGS | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | RECOMMENDATIONS | - |
dc.subject.keywordPlus | FATIGUE | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | DEPRESSION | - |
dc.subject.keywordAuthor | Patient reported outcomes | - |
dc.subject.keywordAuthor | Etanercept | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.subject.keywordAuthor | Asia-Pacific | - |
dc.subject.keywordAuthor | Health outcomes assessments | - |
dc.identifier.url | https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/1471-2474-14-13 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.